Sorry, I don't understand. Please try again

Latest news

Sorry, I don't understand. Please try again

Filters

77 Results

Selected

Clear All

Immunology

New data show TREMFYA® (guselkumab) is the only IL-23 inhibitor proven to significantly inhibit progression of joint structural damage in active psoriatic arthritis

June 11, 2025
Immunology

Icotrokinra results show significant skin clearance in patients with difficult-to-treat scalp and genital psoriasis

May 9, 2025
Immunology

TREMFYA® (guselkumab) delivers sustained clinical and endoscopic remission in ulcerative colitis through two years

May 5, 2025
Immunology

TREMFYA® (guselkumab) positioned to become the first and only IL-23 inhibitor to offer subcutaneous induction in ulcerative colitis as demonstrated in new data through 24 weeks

May 5, 2025
Neuroscience

Johnson & Johnson receives FDA approval for IMAAVY^TM (nipocalimab-aahu), a new FcRn blocker offering long-lasting disease control in the broadest population of people living with generalized myasthenia gravis (gMG)

April 30, 2025
Immunology

Icotrokinra results show 75% of adolescents with plaque psoriasis achieved completely clear skin and demonstrate favorable safety profile in a once daily pill

April 10, 2025